Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug interactions with new hepatitis C oral drugs.
Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Peña JM. Soriano V, et al. Among authors: labarga p. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):333-41. doi: 10.1517/17425255.2015.998997. Epub 2015 Jan 2. Expert Opin Drug Metab Toxicol. 2015. PMID: 25553890 Review.
Emerging drugs for hepatitis C.
Soriano V, Madejon A, Vispo E, Labarga P, Garcia-Samaniego J, Martin-Carbonero L, Sheldon J, Bottecchia M, Tuma P, Barreiro P. Soriano V, et al. Among authors: labarga p. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. doi: 10.1517/14728214.13.1.1. Expert Opin Emerg Drugs. 2008. PMID: 18321145 Review.
Viral hepatitis and HIV co-infection.
Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Soriano V, et al. Among authors: labarga p. Antiviral Res. 2010 Jan;85(1):303-15. doi: 10.1016/j.antiviral.2009.10.021. Epub 2009 Nov 1. Antiviral Res. 2010. PMID: 19887087 Review.
Directly acting antivirals against hepatitis C virus.
Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P. Soriano V, et al. Among authors: labarga p. J Antimicrob Chemother. 2011 Aug;66(8):1673-86. doi: 10.1093/jac/dkr215. Epub 2011 Jun 7. J Antimicrob Chemother. 2011. PMID: 21652618 Review.
Pharmacogenetics of hepatitis C.
Soriano V, Poveda E, Vispo E, Labarga P, Rallón N, Barreiro P. Soriano V, et al. Among authors: labarga p. J Antimicrob Chemother. 2012 Mar;67(3):523-9. doi: 10.1093/jac/dkr506. Epub 2011 Dec 22. J Antimicrob Chemother. 2012. PMID: 22194301
Treatment failure with new hepatitis C drugs.
Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Soriano V, et al. Among authors: labarga p. Expert Opin Pharmacother. 2012 Feb;13(3):313-23. doi: 10.1517/14656566.2012.653341. Epub 2012 Jan 14. Expert Opin Pharmacother. 2012. PMID: 22242928 Review.
The changing face of hepatitis C in the new era of direct-acting antivirals.
Soriano V, Labarga P, Fernández-Montero JV, Benito JM, Poveda E, Rallon N, Sánchez C, Vispo E, Barreiro P. Soriano V, et al. Among authors: labarga p. Antiviral Res. 2013 Jan;97(1):36-40. doi: 10.1016/j.antiviral.2012.10.011. Epub 2012 Nov 9. Antiviral Res. 2013. PMID: 23147192
Hepatitis C therapy with HCV NS5B polymerase inhibitors.
Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P. Soriano V, et al. Among authors: labarga p. Expert Opin Pharmacother. 2013 Jun;14(9):1161-70. doi: 10.1517/14656566.2013.795543. Epub 2013 Apr 27. Expert Opin Pharmacother. 2013. PMID: 23621117 Review.
222 results